review · CNS Neuroscience & Therapeutics

Efficacy of the iron‐chelating agent, deferiprone, in patients with Parkinson's disease: A systematic review and meta‐analysis

202434 citationsOpen accessAlexandria University

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

Current evidence does not support the use of DFP in PD patients. Future disease-modification trials with better population selection, adjustment for concomitant medications, and long-term follow up are recommended.

Research topics

Parkinson's Disease Mechanisms and Treatments
Neurological disorders and treatments
Neurological diseases and metabolism

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1111/cns.14607

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.